Table 2.
The results of Luteolin on different HCC cell lines via different pathways
| Type of cancer | In Vitro/In Vivo | Sex | Module | Sample | Cell line | Luteolin in vitro and in vivo doses | Route of administration | Result | References |
|---|---|---|---|---|---|---|---|---|---|
| HCC | In Vitro | – | – | – | SK-Hep-1 | 0, 20, 40, 80 µM | – |
p-AKT↓, OPN↓, XIAP↓, Mcl-1↓, Bid↓, cleaved Caspase-3↑, cleaved Caspase-8↑, cleaved Caspase-9↑, cleaved PARP↑, |
[27] |
| HCC | In Vitro | – | – | – | Huh-7 | 0, 3.125, 6.25, 12.5, , 25, 50, 100 µM | – |
AKT1↓, SRC↓, p21↑, GADD45↑, DR5 ↑, TRAIL↑, p15↑, HGF↓, FGF↓, VEGF↓, HIFa↓, AKT1↓, CXCL10↓, IFNγ↓, SOCS↓, Bcl-xL↓, MCL1↓, c-MYC↓, CycD↓, p21↑, GFAP↑, BIRC5↑, CDK1↓, CDK2↓, CDK4↓, CDK6↓, CycE↓, CycA↓ |
[28] |
| HCC | In Vivo | ♀ | BALB/c nude | 22 | Huh-7 | 50 mg/kg | Not specified |
miR-6809-5p↑, Ki-67↓, p-Erk1/2↓, p-p38↓, p-JNK↓, p-NF-κB/p65↓, |
[29] |
| HCC | In Vitro | – | – | – |
Huh7 Hep3B |
0, 5, 10, 20 µM | – |
p-JNK↑, DR5↑, LC3-II↑, p62↓, cleaved Caspase-3↑, cleaved caspase-8↑ |
[30] |
| HCC | In Vitro | – | – | – |
Hep3B HepG2 |
0, 1, 2.5, 5, 10 µM | – |
p21↑, cleaved PARP↑, TAP63↓, PCNA↓, LC3-II↑, P62↓ |
[31] |
| HCC | In Vitro | – | – | – |
Huh-7 HepG2 PLC/PRF/5 293T |
0, 20, 40, 60, 80 µM |
– | p-Yap/Yap↑ | [32] |
| HCC | In Vivo | ♀ | BALB/c | 16 | H22 | 50, 100, 200 mg/kg | Gavage |
CD8T(CD3e, CD8a, CCL5, CCL21)↑, Granzyme B↑, INF-γ↑, TNF-a↑, cleaved Caspase-3↑, Caspase-3↑, Bax↑, caspase-8↑, Bcl-2↑, Caspase-9↑ |
[33] |
| HCC | In Vitro | – | – | – | HepG2 |
0, 0.78, 1.56, 3.125, 6.25, 12.5, 25, 50, 100 µg |
– | Induce apoptosis | [34] |
| HCC | In Vitro | – | – | – |
MHCC97-H Hep3B |
0, 0.625, 1.25, 2.5, 5 µg/ml |
– |
cleaved PARP↑, cleaved Caspase-3↑, cleaved caspase-8↑, proCaspase-3↓, procaspase-8↓, XIAP↓ |
[35] |
| HCC | In Vivo | ♀ | BALB/c nude | 32 | MHCC97-H | 50 mg/kg | Intraperitoneal injection |
IL-24↑, CD31↓, Ki67↓, Caspase-3↑ |
[35] |
| HCC | In Vitro | – | – | – | HepG2 | 0, 10, 20, 100 µg/ml | – | Bcl-2↓, LDH↑ | [36] |
| HCC | In Vitro | – | – | – | HepG2 | 24 µg/ml | – | Induce apoptosis and autophagy | [37] |
| HCC | In Vivo | ♂ | CD-1 | 80 | EAC | 10 mg/kg | Intraperitoneal injection | Inhibit tµMor growth | [37] |
| HCC | In Vivo | ♂ | Wistar | 90 | – | 10 mg/kg | Gavage |
GPC3↓, NO↓, MDA↓, GSH↑, SOD↑ |
[38] |
“↑”indicates up-regulation, “↓”indicates down-regulation, and - indicates cell administration or an unknown route of administration or gender